Nilotinib

Nilotinib, the active ingredient in Nilotinib, is a tyrosine kinase inhibitor presented as an oral tablet for systemic use. It is indicated for chronic myeloid leukemia in chronic or accelerated phase after imatinib resistance or intolerance, and for Philadelphia chromosome‑positive acute lymphoblastic leukemia. All batches are manufactured under GMP conditions and undergo rigorous quality testing before release.

GNH USA supplies Nilotinib as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with distribution aligned to EU market standards.

Nilotinib is used to target BCR‑ABL–positive leukemias, addressing disease mechanisms driven by abnormal tyrosine kinase activity. - Chronic myeloid leukemia (CML): improves disease control in patients resistant or intolerant to imatinib. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): provides an alternative targeted therapy for patients with BCR‑ABL positivity.

Nilotinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Rash: mild skin eruptions or itching. - Nausea: occasional gastrointestinal upset. - Diarrhea: loose stools that may be transient. - Elevated liver enzymes: mild increases in ALT or AST.

Serious or Rare Side Effects: - Cardiovascular events: arterial occlusion, ischemic heart disease, or stroke. - Severe hepatotoxicity: marked elevation of liver enzymes or hepatitis. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - QT interval prolongation: risk of cardiac arrhythmia requiring monitoring.

When prescribing Nilotinib, clinicians should observe several safety precautions to minimize risks. - Cardiac monitoring: assess baseline ECG and monitor QT interval during therapy. - Liver function: check hepatic enzymes before initiation and periodically thereafter. - Pancreatic enzymes: evaluate amylase and lipase levels regularly. - Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors or inducers. - Pregnancy risk: contraindicated in pregnancy; advise effective contraception for women of childbearing potential. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Nilotinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise Nilotinib levels and risk severe side effects. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can lower drug exposure, reducing efficacy. - Antacids containing aluminum or magnesium: reduce absorption if taken within 2 hours of Nilotinib.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors (e.g., omeprazole): may modestly decrease absorption; timing adjustment recommended. - Statins metabolized by CYP3A4 (e.g., simvastatin, atorvastatin): increased risk of statin‑related muscle toxicity. - Anticoagulants (e.g., warfarin): monitor INR as Nilotinib may affect clotting parameters.